Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Baxalta | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Baxalta

Newly launched, independent company gains momentum

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Baxalta

2Q Revenues: $1.4 billion (-2%)

2Q Earnings: $272 million (-24%)

YTD Revenues: $2.8 billion (flat)

YTD Earnings: n/a

Comments: Hematology revenues were $855 million, excluding the impact of foreign exchange, grew 6% in the quarter driven by ADVATE, a treatment for hemophilia A, and double-digit growth of FEIBA, an inhibitor treatment. Newly launched products also contributed to growth, including RIXUBIS for the treatment of hemophilia B, and OBIZUR for the treatment of acquired hemophilia A. Immunology sales were $574 million, excluding the impact of foreign currency, grew 10% driven by immunoglobulin therapies and continued launch success of HYQVIA for adults with primary immunodeficiency. In the quarter, the company completed the ONCASPAR portfolio acquisition from Sigma-Tau Finanziaria for approximately $900 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics